Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.22B | $4.37B | $5.08B | $5.45B | $5.53B | $6.20B | $4.61B | $4.83B | $5.19B | $5.45B |
| Revenue growth | — | 3.5% | 16.4% | 7.3% | 1.4% | 12.2% | -25.7% | 4.7% | 7.5% | 5.1% |
| Operating income | $300M | $356M | $417M | $472M | $568M | $714M | $145M | $267M | $268M | $336M |
| Operating margin | 7.1% | 8.2% | 8.2% | 8.7% | 10.3% | 11.5% | 3.1% | 5.5% | 5.2% | 6.2% |
| Net income | $115M | $177M | $138M | $148M | $259M | $402M | $159M | $243M | $214M | $146M |
| Net margin | 2.7% | 4.1% | 2.7% | 2.7% | 4.7% | 6.5% | 3.4% | 5.0% | 4.1% | 2.7% |
| EPS (diluted) | $0.87 | $1.33 | $1.02 | $1.10 | $1.93 | $2.98 | $1.23 | $1.91 | $1.66 | $1.16 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $347M | $238M | $494M | $445M | $1.03B | $401M | $285M | $582M | $518M | $346M |
| Capital expenditures | $162M | $233M | $167M | $157M | $146M | $181M | $190M | $229M | $222M | $229M |
| Free cash flow | $185M | $4.89M | $327M | $288M | $882M | $221M | $94.5M | $353M | $296M | $117M |
| Dividends paid | $0.00 | $0.00 | — | $0.00 | $0.00 | $50.6M | $64.6M | $63.9M | $64.6M | $31.4M |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $99.0M | $123M | $175M | $336M | $577M | $74.3M | $97.9M | $52.6M | $59.7M | $26.5M |
| Total assets | $4.92B | $5.13B | $5.96B | $7.34B | $7.66B | $7.36B | $7.67B | $7.69B | $5.61B | $5.85B |
| Total liabilities | $3.59B | $3.55B | $4.27B | $5.44B | $6.00B | $6.00B | $6.27B | $6.12B | $3.61B | $3.82B |
| Long-term debt | $2.70B | $2.70B | $3.29B | $3.45B | — | — | — | — | — | — |
| Shareholders' equity | $816M | $823M | $803M | $771M | $1.06B | $1.11B | $1.12B | $1.29B | $1.68B | $1.71B |
| Retained earnings | $372M | $360M | $320M | $280M | $553M | $593M | $581M | $752M | $770M | $837M |
| Shares (wtd avg diluted) | 128M | 129M | 130M | 130M | 130M | 130M | 125M | 123M | 125M | 123M |
Every figure is extracted from SELECT MEDICAL HOLDINGS CORP’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.